


CLAIMS

1. Use of a compound corresponding to formula (I):



5 in which:

- W represents a nitrogen atom or a group CH;
- Y represents a group C₂-C₃-alkynylene, or a 1,4-phenylene optionally substituted with R₇ which represents one or more halogen atom(s);

- Z represents a bond or a group CR₁R₂;

10 - R₁ and R₂, independently of each other, represent a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a trifluoromethyl group, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an heteroaryl or an aryl optionally substituted with one or more halogen atom(s);

- R₁ and R₂ can form together, with the carbon atom which bear them, a C₃-C₇-cycloalkyl;

15 - R₃ represents a hydrogen atom;

- R₄ represents a group chosen from a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl or C₁-C₆-alkyl optionally substituted by a C₃-C₇-cycloalkyl;

- R₅ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

- R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

20 - n is equal to 1, 2 or 3;

in the form of the base or of an acid-addition salt; or

a pharmaceutically acceptable salt thereof; or

an enantiomer or a diastereoisomer; or

a mixture thereof;

25 in the manufacture of a medicament for preventing and/or treating diseases in which VEGFR-3 is involved, said disease being chosen from cancer and metastases, more particularly glioblastomas, multiple myelomas, myelodysplastic syndromes, Kaposi's sarcomas, cutaneous angiosarcomas, solid tumours, lymphomas, melanomas, breast cancers,

colorectal cancers, lung cancers, including non-small-cell cancers, pancreatic cancers, prostate cancers, kidney cancers, head and neck cancers, liver cancer, ovarian cancers, cancers of the respiratory tract and chest, or other tumours expressing VEGFR-3 or involving a process of angiogenesis or of lymphangiogenesis; diseases in which VEGFR-3 is involved chosen from

5 non-oncological proliferative disease or pathological angiogenesis; and disease selected from the group consisting of arthrosis, restenosis, psoriasis, hemangiomas, lymphangiomas, glaucomas, glomerulonephritis, diabetic nephropathies, nephrosclerosis, thrombotic microangiopathic syndromes, liver cirrhosis, atherosclerosis, organ transplant rejection, or eye diseases involving a process of angiogenesis or of lymphangiogenesis or chronic or non-

10 chronic inflammation, infection with microorganisms and of autoimmune diseases, such as rheumatoid arthritis or rare diseases such as lymphagioleiomyomatosis or Gorham's Disease.

2. The use according to claim 1, wherein the disease is cancer and metastases, more particularly glioblastomas, multiple myelomas, myelodysplastic syndromes, Kaposi's sarcomas, cutaneous angiosarcomas, solid tumours, lymphomas, melanomas, breast cancers, colorectal cancers, lung cancers, including non-small-cell cancers, pancreatic cancers, prostate cancers, kidney cancers, head and neck cancers, liver cancer, ovarian cancers, cancers of the respiratory tract and chest, or other tumours expressing VEGFR-3 or involving a process of angiogenesis or of lymphangiogenesis.

3. The use according to claim 1, wherein the disease in which VEGFR-3 is involved is non-oncological proliferative disease or pathological angiogenesis.

4. The use according to claim 1, wherein the disease is selected from the group consisting of arthrosis, restenosis, psoriasis, hemangiomas, lymphangiomas, glaucomas, glomerulonephritis, diabetic nephropathies, nephrosclerosis, thrombotic microangiopathic syndromes, liver cirrhosis, atherosclerosis, organ transplant rejection, or eye diseases involving a process of angiogenesis or of lymphangiogenesis or chronic or non-chronic inflammation, infection with microorganisms and of autoimmune diseases, such as rheumatoid arthritis or rare diseases such as lymphagiroleiomyomatosis or Gorham's Disease.

5. The use according to any of claims 1-4, wherein W represents a nitrogen atom.

6. The use according to any of claims 1-5, wherein Y represents a group C₂-C₃-alkynylene, more particularly ethynylene.

7. The use according to any of claims 1-6, wherein:

- Z represents a bond, or a group CR₁R₂; more particularly a group CR₁R₂;
- R₁ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl;
- R₂ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl or a trifluoromethyl group;
- R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;
- n is equal to 1, 2 or 3.

8. The use according to any of claims 1-7, wherein R₄ represents a group C₁-C₆-alkyl, and more particularly an ethyl.

9. The use according to any of claims 1-8, wherein R₅ represents a hydrogen atom.

5

10. The use according to any of claims 1-9, wherein:

- W represents a nitrogen atom or a group CH;
- Y represents a group C₂-C₃-alkynylene or a 1,4-phenylene optionally substituted

with R₇ which represents a halogen atom;

10

- Z represents a bond, or a group CR₁R₂;

- R₁ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl, an aryl or a 5- or 6-membered-heteroaryl optionally substituted with a halogen atom;

- R₂ represents a group chosen from a hydrogen atom, a group C₁-C₆-alkyl or a

15

trifluoromethyl group;

- R₃ represents a hydrogen atom ;

- R₄ represents a group chosen from a group C₁-C₆-alkyl, a group (CH₂)_nOR₆, C₃-C₇-cycloalkyl or C₁-C₆-alkyl optionally substituted by a C₃-C₇-cycloalkyl;

- R₅ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

20

- R₆ represents a group chosen from a hydrogen atom or a group C₁-C₆-alkyl;

- n is equal to 1, 2 or 3.

11. The use according to any of claims 1-10, wherein R₁ and R₂ form together, with the carbon atom which bear them, a C₃-C₇-cycloalkyl.

25

12. The use according to any of claims 1-4, wherein the compound is chosen from:

2-Amino-1-ethyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-propyl-7-((3R)-3-hydroxy-4-methoxy-3-methyl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

30

2-Amino-7-(3,4-dihydroxy-3-methyl-but-1-ynyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one

2-Amino-1-ethyl-7-(-3-hydroxy-3-pyridin-2-yl-but-1-ynyl)-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one